Shares of Strides Pharma Science hit a 52-week high of Rs 522.20, soaring 11 per cent on the BSE in Friday's intraday trade, after the company received a tentative approval from the US health regulator for generic Dolutegravir tablets used in the treatment of HIV.
Dolutegravir tablets belong to a class of medication knows as antiretrovirals. This medication is the first line of antiretroval therapy (ART) for treatment naïve patients. It works by preventing the multiplication of the virus in human cells.
"The Abbreviated New Drug Application (ANDA) is tentatively approved under USFDA's expedited review provision for the President's Emergency Plan for AIDS Relief, thereby qualifying the company to participate in global donor-funded programmes that procure this lifesaving medicine,: it said.
This product further strengthens the available offerings in HIV treatment from Strides, the company said.
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Tivicay Tablets of ViiV Healthcare Company. The approval adds to a list of products that Strides has approved under the PEPFAR pathway taking the total to 13 products.
At 10:49 AM, Strides was trading 9 per cent higher at Rs 508.35, as compared to 0.22 per cent rise in the S&P BSE Sensex. It surpassed its previous high of Rs 490 touched on September 8, 2023. Trading volumes on the counter jumped over five-fold today with a combined 4.4 million equity shares having changed hands on the NSE and BSE till the time of writing of this report.
Strides, a global pharmaceutical company, specialises in developing and manufacturing niche finished dosage formulations. The company’s product portfolio encompasses a range of technically complex pharmaceutical products, including liquids, creams, ointments, soft gels, sachets, tablets, and modified-release dosage formats.
Strides Pharma Q1FY24 results: Net profit at Rs 8 cr; revenue up 12%
Aurobindo Pharma to launch HIV drug for children in 123 countries
Sun Pharma Q1 net profit drops 2% YoY, Revenue up 11%; US sales at $471 mn
Mankind Pharma IPO to open next week: Check price band, GMP, other details
Sun Pharma Q1 profit may be weighed by weak US generic sales and Taro nos
Bajaj Auto zooms 5% to hit new high, tops Rs 5000 on BofA's double-upgrade
Is Nifty PSU Bank nearing an interim peak? Keep an eye on this pivot point
Midcap stocks have room to correct; buy the dips: Chris Wood
Restaurant Brands Asia rallies 13%, hits 52-week high on large block deal
Stock Market LIVE: Indices at new highs for second day; Bajaj Auto zooms 5%
Thus far in the financial year 2023-24 (FY24), the stock price of Strides has zoomed 82 per cent.
With further resetting of the existing businesses and accomplishing all the works that commenced at the beginning of the year, the company said it's building momentum for its businesses in FY 2023-24.
"The company is confident of increasing its Ebitda from current levels and intends to achieve net debt to Ebitda ratio of less than 3x. Key focus shall remain on manufacturing network optimisation, new product launches and market expansion. The company shall also continue to work on various cost improvement programs," Strides said in its FY23 annual report.